Therapeutic approach by Aloe vera in experimental model of multiple sclerosis

References

• Peiris, M., Monteith, G.R., Roberts-Thomson, S.J., Cabot, P.J. A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of intervention therapies. J. Neurosci. Methods. 2007, 163, 245–254.
   PubMed Web of Science ®Google Scholar
• Furlan, R., Kurne, A., Bergami, A., Brambilla, E., Maucci, R., Gasparini, L., Butti, E., Comi, G., Ongini, E., Martino, G. A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2004, 150, 10–19.
   PubMed Web of Science ®Google Scholar
• Zaheer, S., Wu, Y., Bassett, J., Yang, B., Zaheer, A. Glia maturation factor regulation of STAT expression: a novel mechanism in experimental autoimmune encephalomyelitis. Neurochem. Res. 2007, 32, 2123–2131.
   PubMedGoogle Scholar
• Wang, Y., Kai, H., Chang, F., Shibata, K., Tahara-Hanaoka, S., Honda, S., Shibuya, A., Shibuya, K. A critical role of LFA-1 in the development of Th17 cells and induction of experimental autoimmune encephalomyelytis. Biochem. Biophys. Res. Commun. 2007, 353, 857–862.
   PubMed Web of Science ®Google Scholar
• Xiao, B.G., Ma, C.G., Xu, L.Y., Link, H., Lu, C.Z. IL-12/IFN-gamma/NO axis plays critical role in development of Th1-mediated experimental autoimmune encephalomyelitis. Mol. Immunol. 2008, 45, 1191–1196.
   PubMedGoogle Scholar
• Jiang, H.R., Al Rasebi, Z., Mensah-Brown, E., Shahin, A., Xu, D., Goodyear, C.S., Fukada, S.Y., Liu, F.T., Liew, F.Y., Lukic, M.L. Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J. Immunol. 2009, 182, 1167–1173.
   PubMedGoogle Scholar
• Fisher, A.E., Maxwell, S.C., Naughton, D.P. Superoxide and hydrogen peroxide suppression by metal ions and their EDTA complexes. Biochem. Biophys. Res. Commun. 2004, 316, 48–51.
   PubMed Web of Science ®Google Scholar
• Klein, A.D., Penneys, N.S. Aloe vera. J.Am. Acad. Dermatol. 1988, 18, 714–720.
   PubMed Web of Science ®Google Scholar
• Grindlay, D., Reynolds, T. The Aloe vera phenomenon: a review of the properties and modern uses of the leaf parenchyma gel. J. Ethnopharmacol. 1986, 16, 117–151.
   PubMed Web of Science ®Google Scholar
• Eamlamnam, K., Patumraj, S., Visedopas, N., Thong-Ngam, D. Effects of Aloe vera and sucralfate on gastric microcirculatory changes, cytokine levels and gastric ulcer healing in rats. World J. Gastroenterol. 2006, 12, 2034–2039.
   PubMed Web of Science ®Google Scholar
• Davis, R.H., Leitner, M.G., Russo, J.M., Byrne, M.E. Wound healing. Oral and topical activity of Aloe vera. J. Am. Podiatr. Med. Assoc. 1989, 79, 559–562.
   PubMed Web of Science ®Google Scholar
• Shelton, R.M. Aloe vera. Its chemical and therapeutic properties. Int. J. Dermatol. 1991, 30, 679–683.
   PubMed Web of Science ®Google Scholar
• Langmead, L., Chitnis, M., Rampton, D.S. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm. Bowel Dis. 2002, 8, 174–179.
   PubMed Web of Science ®Google Scholar
• Sampedro, M.C., Artola, R.L., Murature, M., Murature, D., Ditamo, Y., Roth, G.A., Kivatinitz, S. Mannan from Aloe saponaria inhibits tumoral cell activation and proliferation. Int. Immunopharmacol. 2004, 4, 411–418.
   PubMedGoogle Scholar
• Reynolds, T., Dweck, A.C. Aloe vera leaf gel: a review update. J. Ethnopharmacol. 1999, 68, 3–37.
   PubMed Web of Science ®Google Scholar
• Wooles, W.R., Diluzio, N.R. Reticuloendothelial function and the immune response. Science. 1963, 142, 1078–1080.
   PubMedGoogle Scholar
• Rajasekaran, S., Sivagnanam, K., Subramanian, S. Antioxidant effect of Aloe vera gel extract in streptozotocin-induced diabetes in rats. Pharmacol. Rep. 2005, 57, 90–96.
   PubMed Web of Science ®Google Scholar
• Cory-Slechta, D.A., Weiss, B. Efficacy of the chelating agent CaEDTA in reversing lead-induced changes in behavior. Neurotoxicology. 1989, 10, 685–697.
   PubMed Web of Science ®Google Scholar
• Meldrum, J.B., Ko, K.W. Effects of calcium disodium EDTA and meso-2,3-dimercaptosuccinic acid on tissue concentrations of lead for use in treatment of calves with experimentally induced lead toxicosis. Am. J. Vet. Res. 2003, 64, 672–676.
   PubMed Web of Science ®Google Scholar
• Skundric, D.S., Zakarian, V., Dai, R., Lisak, R.P., Tse, H.Y., James, J. Distinct immune regulation of the response to H-2b restricted epitope of MOG causes relapsing-remitting EAE in H-2b/s mice. J. Neuroimmunol. 2003, 136, 34–45.
   PubMedGoogle Scholar
• Natarajan, C., Muthian, G., Barak, Y., Evans, R.M., Bright, J.J. Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J. Immunol. 2003, 171, 5743–5750.
   PubMedGoogle Scholar
• Phizackerley, P.J., Al-Dabbagh, S.A. The estimation of nitrate and nitrite in saliva and urine. Anal. Biochem. 1983, 131, 242–245.
   PubMedGoogle Scholar
• Tuohy, V.K., Lu, Z., Sobel, R.A., Laursen, R.A., Lees, M.B. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J. Immunol. 1989, 142, 1523–1527.
   PubMed Web of Science ®Google Scholar
• Mendel, I., Kerlero de Rosbo, N., Ben-Nun, A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur. J. Immunol. 1995, 25, 1951–1959.
   PubMed Web of Science ®Google Scholar
• McRae, B.L., Kennedy, M.K., Tan, L.J., Dal Canto, M.C., Picha, K.S., Miller, S.D. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J. Neuroimmunol. 1992, 38, 229–240.
   PubMed Web of Science ®Google Scholar
• Beck, J., Rondot, P., Catinot, L., Falcoff, E., Kirchner, H., Wietzerbin, J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol. Scand. 1988, 78, 318–323.
   PubMed Web of Science ®Google Scholar
• Miller, A., al-Sabbagh, A., Santos, L.M., Das, M.P., Weiner, H.L. Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. J. Immunol. 1993, 151, 7307–7315.
   PubMed Web of Science ®Google Scholar
• Chen, Y., Kuchroo, V.K., Inobe, J., Hafler, D.A., Weiner, H.L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994, 265, 1237–1240.
   PubMed Web of Science ®Google Scholar
• Racke, M.K., Bonomo, A., Scott, D.E., Cannella, B., Levine, A., Raine, C.S., Shevach, E.M., Röcken, M. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 1994, 180, 1961–1966.
   PubMed Web of Science ®Google Scholar
• Acar, G., Idiman, F., Idiman, E., Kirkali, G., Cakmakçi, H., Ozakbas, S. Nitric oxide as an activity marker in multiple sclerosis. J. Neurol. 2003, 250, 588–592.
   PubMed Web of Science ®Google Scholar
• Smith, K.J., Lassmann, H. The role of nitric oxide in multiple sclerosis. Lancet. Neurol. 2002, 1, 232–241.
   PubMed Web of Science ®Google Scholar
• Rand, M.J. Nitrergic transmission: nitric oxide as a mediator of non-adrenergic, non-cholinergic neuro-effector transmission. Clin. Exp. Pharmacol. Physiol. 1992, 19, 147–169.
   PubMed Web of Science ®Google Scholar
• Toda, N., Tanaka, T., Ayajiki, K., Okamura, T. Cerebral vasodilatation induced by stimulation of the pterygopalatine ganglion and greater petrosal nerve in anesthetized monkeys. Neuroscience. 2000, 96, 393–398.
   PubMed Web of Science ®Google Scholar
• Redford, E.J., Kapoor, R., Smith, K.J. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain. 1997, 120 (Pt 12), 2149–2157.
   PubMedGoogle Scholar
• Kapoor, R., Davies, M., Smith, K.J. Temporary axonal conduction block and axonal loss in inflammatory neurological disease. A potential role for nitric oxide? Ann. N. Y. Acad. Sci. 1999, 893, 304–308.
   PubMedGoogle Scholar
• Garthwaite, G., Goodwin, D.A., Batchelor, A.M., Leeming, K., Garthwaite, J. Nitric oxide toxicity in CNS white matter: an in vitro study using rat optic nerve. Neuroscience. 2002, 109, 145–155.
   PubMedGoogle Scholar
• Allione, A., Bernabei, P., Bosticardo, M., Ariotti, S., Forni, G., Novelli, F. Nitric oxide suppresses human T lymphocyte proliferation through IFN-gamma-dependent and IFN-gamma-independent induction of apoptosis. J. Immunol. 1999, 163, 4182–4191.
   PubMedGoogle Scholar
• Dietlin, T.A., Hofman, F.M., Gilmore, W., Stohlman, S.A., van der Veen, R.C. T cell expansion is regulated by activated Gr-1+ splenocytes. Cell. Immunol. 2005, 235, 39–45.
   PubMedGoogle Scholar